Hyperlipidemia Drugs Market Poised for Steady Growth in the Future By 2022

The global hyperlipidemia drugs market size is expected to reach USD 22.6 billion by 2022, according to a new report by Grand View Research, Inc., expanding at a CAGR of 2.3% during the forecast period. Several factors, such as an increase in target population and growth in awareness about the risk of Cardiovascular Diseases (CVD) due to persistent hypercholesterolemia, are stoking the growth of the market.

Hyperlipidemia is the most common type of dyslipidemia and is generally caused by abnormally high lipid levels in the blood. This condition can occur due to genetic factors (primary hyperlipidemia) as well as other factors such as poor diet and unhealthy lifestyle (secondary hyperlipidemia). Statins are the first line of treatment for secondary hyperlipidemia.

The target population of antihyperlipidemic drugs is broadly divided into statin users and nonstatin users. The revenue share of statin users has been declining. The nonstatin users segment consists of a statin-intolerant and nonresponsive population as well as familial hyperlipidemia (FH) population. Nonstatin users are seeking high-efficacy alternatives and this is anticipated to boost the revenue of this segment.

Recent Market Developments

In April 2020, it came to light that AstraZeneca will take a $100m writedown after trials of a heart disease drug called Epanova, showed it to be ineffective in treating a particular cardiovascular condition(Hyperlipidemia). After the disappointing results, the pharmaceutical group said it would discontinue trials on the drug, known as Epanova, and carry out a review into its $533m value on the company’s balance sheet. This will be a small hindrance for the growth of the company; however, riding over its R&D, it is bound to recover quickly.

In March 2020, Novartis announcesd NEJM publication of three pivotal trials showing durable and potent efficacy of inclisiran, an investigational first-in-class siRNA cholesterol-lowering therapy, which has tremendous efficacy in the treatment of hyperlipidemia. The primary endpoints were achieved in all three trials. Namely, percentage change in LDL-C from baseline to 17 months and time-adjusted percentage change in LDL-C from baseline from 3 through 18 months. This demonstrates that after two starter doses, twice-yearly subcutaneous dosing with inclisiran resulted in durable and potent LDL-C reductions versus placebo. Inclisiran was well-tolerated with a safety profile similar to placebo. This has been a major development in development of a new and safe drug, helping the affected patients 

In January 2020, Novartis also completed acquisition of The Medicines Company, which proved to be a remarkable step, as it helped Novartis to complete the 3 trials, crucial in deciding the efficacy of Inclisiran. Acquiring The Medicines Company and inclisiran gives Novartis a unique opportunity to open up a new chapter on the treatment of the world’s leading cause of mortality and disability with a vaccine-like approach. It’s a significant step forward on their journey to focus the company, to reimagine medicine, and to bend the curve of life. This increases the market value of the company and provides a nnew effective drug to the patients to tackle the health issue.

In January 2020, National Health Service decided to launch a mass trial of an as-yet unapproved twice-yearly cholesterol-lowering injection called inclisiran, which it hopes will save lives and cut medical bills for thousands of people who do not take statins. About 40,000 people with high “bad” or low-density lipoprotein cholesterol will be invited to join the trial of inclisiran by NHS England via their GPs. The NHS has struck a novel deal with drugmaker Novartis, which will provide the injections free in exchange for the results of the five-year trial, which will be run by the NHS staff. This  step is definitely going to boost the popularity of the drug and also verify its positive claims. 

In October 2019, Akcea Therapeutics, Inc., a majority-owned affiliate of Ionis Pharmaceuticals, Inc. and Pfizer Inc. announced that the companies entered into a worldwide exclusive licensing agreement for AKCEA-ANGPTL3-LRx, an investigational antisense therapy being developed to treat patients with certain cardiovascular and metabolic diseases. AKCEA-ANGPTL3-LRx is designed to reduce the production of angiopoietin-like 3 (ANGPTL3) proteins in the liver, a key regulator of triglycerides, cholesterol, glucose and energy metabolism. AKCEA-ANGPTL3-LRx is currently being evaluated in a Phase 2 study in patients with Type 2 diabetes, hypertriglyceridemia and non-alcoholic fatty liver disease (NAFLD). This collaboration is bound to be helpful in the longer run to find better vaccines and drugs for hypertryglyceridemia.

Request a free sample copy or view report summary: https://www.grandviewresearch.com/industry-analysis/hyperlipidemia-drugs-market 

In June 2019, The merger of Pfizer’s off-patent drugs business UpJohn with generic drugs company Mylan gave a boost to the New York City-headquartered pharmaceuticals firm’s business in several countries, especially in developing countries like India. Along with other drugs, getting a solid boost, drugs for peculiar heart conditions are also going t o receive a tremendous push in manufacturing, as a large market  has opened itself to both of them and improved their reach all around. 

In 2016, USFDA refused to approve Zetia and Vytorin, Merck’s medicines that are used to reduce the risk of cardiovascular events in patients with coronary heart disease. Zetia and Vytorin are indicated for use along with a healthy diet to reduce elevated low-density lipoprotein (LDL) cholesterol in patients with hyperlipidemia. However, both the drugs could not satisfy the conditions and stand rejected as of now. 

In March 2020, Amgen Announces Positive Results At ACC.20/WCC From Phase 3B Study Of Repatha (Evolocumab) In People Living With HIV Who Have High LDL-Cholesterol. The study demonstrated that treatment with Repatha significantly reduced LDL-C. The results were featured as an oral presentation during the virtual American College of Cardiology's 69^th Annual Scientific Session from March 28-30, 2020 with publication in the Journal of the American College of Cardiology (JACC). atients treated with Repatha also demonstrated improved secondary outcomes versus placebo with 71.9% of patients achieving an LDL-C reduction of more than or equal to 50% from baseline and 65.4% of patients achieving an LDL-C of less than 70 mg/dL. This study opens up a new drug to alleviate the problems of hyperlipidemia affected HIV people. 

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.